

# Lucia Taramasso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5565011/publications.pdf>

Version: 2024-02-01

105  
papers

2,615  
citations

304743

22  
h-index

214800

47  
g-index

109  
all docs

109  
docs citations

109  
times ranked

4785  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	13.7	627
2	Bloodstream infections in critically ill patients with COVID-19. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13319.	3.4	203
3	Epidemiology, Species Distribution, Antifungal Susceptibility and Outcome of Nosocomial Candidemia in a Tertiary Care Hospital in Italy. <i>PLoS ONE</i> , 2011, 6, e24198.	2.5	164
4	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 555.	2.4	93
5	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <i>PLoS ONE</i> , 2020, 15, e0237831.	2.5	85
6	Spread of Carbapenem-Resistant Gram-Negatives and <i>Candida auris</i> during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship?. <i>Microorganisms</i> , 2021, 9, 95.	3.6	77
7	Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. <i>Journal of Clinical Medicine</i> , 2020, 9, 2780.	2.4	71
8	Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 585-596.	4.4	68
9	Weight Gain: A Possible Side Effect of All Antiretrovirals. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx239.	0.9	68
10	Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw557.	3.0	62
11	HIV-Associated Neurocognitive Impairment in the Modern ART Era: Are We Close to Discovering Reliable Biomarkers in the Setting of Virological Suppression?. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 187.	3.4	55
12	Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. <i>Journal of Nephrology</i> , 2021, 34, 173-183.	2.0	52
13	Factors Associated With Weight Gain in People Treated With Dolutegravir. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa195.	0.9	47
14	The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. <i>Aids</i> , 2020, 34, 877-881.	2.2	47
15	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. <i>PLoS Pathogens</i> , 2021, 17, e1009448.	4.7	43
16	Will new antimicrobials overcome resistance among Gram-negatives?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 909-922.	4.4	42
17	Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). <i>BMC Infectious Diseases</i> , 2018, 18, 357.	2.9	42
18	Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study. <i>Infection</i> , 2016, 44, 589-597.	4.7	39

#	ARTICLE	IF	CITATIONS
19	Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells. <i>Journal of Virology</i> , 2017, 91, .	3.4	39
20	Duration of quarantine in hospitalized patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: a question needing an answer. <i>Journal of Hospital Infection</i> , 2020, 105, 404-405.	2.9	39
21	Bloodstream infections in HIV-infected patients. <i>Virulence</i> , 2016, 7, 320-328.	4.4	38
22	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1955-1964.	3.0	29
23	Factors associated with hospital admission for COVID-19 in HIV patients. <i>Aids</i> , 2020, 34, 1983-1985.	2.2	26
24	CD8+CD28 <sup>hi</sup> CD127 <sup>lo</sup> CD39 <sup>+</sup> regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection?. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2220-2233.e4.	2.9	22
25	Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. <i>PLoS ONE</i> , 2019, 14, e0223181.	2.5	22
26	Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era: Neglected no more?. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005237.	3.0	22
27	Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients. <i>Journal of Hypertension</i> , 2017, 35, 409-416.	0.5	21
28	Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1862-1871.	3.0	20
29	Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1385-1391.	2.7	19
30	Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2018, 13, 3-11.	0.8	18
31	How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis. <i>Journal of Clinical Virology</i> , 2020, 123, 104255.	3.1	18
32	Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 54-58.	1.2	16
33	Treatment of hepatitis C virus genotype 4 in the DAA era. <i>Virology Journal</i> , 2018, 15, 180.	3.4	16
34	Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 119-127.	2.1	15
35	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. <i>AIDS Patient Care and STDs</i> , 2021, 35, 342-353.	2.5	15
36	Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study. <i>BMC Public Health</i> , 2020, 20, 734.	2.9	15

#	ARTICLE	IF	CITATIONS
37	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3295-3304.	3.0	14
38	Pineal Germinoma in a Child with Interferon- $\beta$ Receptor 1 Deficiency. Case Report and Literature Review. <i>Journal of Clinical Immunology</i> , 2014, 34, 922-927.	3.8	13
39	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018, 19, 475-484.	2.2	13
40	The impact of DAA-mediated HCV eradication on CD4 <sup>+</sup> and CD8 <sup>+</sup> T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 779-786.	2.0	12
41	Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 551-554.	2.5	11
42	Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 387-398.	4.0	11
43	Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade. <i>HIV Medicine</i> , 2022, 23, 70-79.	2.2	11
44	Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression. <i>Vaccines</i> , 2022, 10, 1141.	4.4	11
45	Duration of isolation and precautions in immunocompromised patients with COVID-19. <i>Journal of Hospital Infection</i> , 2021, 111, 202-204.	2.9	10
46	<i>Aspergillus</i> PCR in bronchoalveolar lavage - diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patients. <i>Mycoses</i> , 2022, 65, 411-418.	4.0	10
47	Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 233-236.	5.6	8
48	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1443-1446.	6.0	8
49	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. <i>Microorganisms</i> , 2020, 8, 2010.	3.6	8
50	Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care. <i>European Journal of Internal Medicine</i> , 2021, 94, 39-44.	2.2	8
51	Reversibility of Central Nervous System Adverse Events in Course of Art. <i>Viruses</i> , 2022, 14, 1028.	3.3	8
52	Case report: Management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. <i>Journal of Medical Virology</i> , 2012, 84, 1340-1343.	5.0	7
53	Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, e76-e79.	1.5	7
54	How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy. <i>BMC Health Services Research</i> , 2018, 18, 691.	2.2	7

#	ARTICLE	IF	CITATIONS
55	Missed opportunities to prevent mother-to-child transmission of HIV in Italy. <i>HIV Medicine</i> , 2019, 20, 330-336.	2.2	7
56	Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study. <i>Microorganisms</i> , 2020, 8, 864.	3.6	7
57	Injectable Antiretroviral Drugs: Back to the Future. <i>Viruses</i> , 2021, 13, 228.	3.3	7
58	Bloodstream infections in patients living with HIV in the modern cART era. <i>Scientific Reports</i> , 2019, 9, 5418.	3.3	6
59	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (IN ACTION) cohort. <i>HIV Medicine</i> , 2020, 21, 523-535.	2.2	6
60	Real-World Analysis of Survival and Clinical Events in a Cohort of Italian Perinatally HIV-1 Infected Children From 2001 to 2018. <i>Frontiers in Pediatrics</i> , 2021, 9, 665764.	1.9	6
61	Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2018, 13, e0192627.	2.5	6
62	Epidemiological and Clinical Features of Hepatitis Delta in HBsAg-Positive Patients by HIV Status. <i>Antiviral Therapy</i> , 2015, 20, 193-197.	1.0	6
63	HIV-1 RNA quantification in CRF02_AG HIV-1 infection: too easy to make mistakes. <i>New Microbiologica</i> , 2016, 39, 150-2.	0.1	6
64	Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports. <i>International Journal of STD and AIDS</i> , 2015, 26, 831-834.	1.1	5
65	Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study. <i>Epidemiology and Infection</i> , 2017, 145, 1658-1669.	2.1	5
66	Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing. <i>ERJ Open Research</i> , 2018, 4, 00108-2017.	2.6	5
67	Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA). <i>AIDS Research and Therapy</i> , 2019, 16, 21.	1.7	5
68	Pneumocystis jirovecii pneumonia in HIV-negative patients, a frequently overlooked problem. A case series from a large Italian center. <i>International Journal of Infectious Diseases</i> , 2022, 121, 172-176.	3.3	5
69	Therapeutic Management of Chronic Hepatitis B in Clinical Practice. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 228-234.	2.2	4
70	Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?. <i>BMC Infectious Diseases</i> , 2017, 17, 127.	2.9	4
71	Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019, 18, 232595821882165.	1.5	4
72	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13358.	3.4	4

#	ARTICLE	IF	CITATIONS
73	Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B. <i>Journal of Medical Virology</i> , 2011, 83, 1905-1908.	5.0	3
74	HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 189-193.	1.4	3
75	Will vaccine hesitancy compromise our efforts to face the next SARS-CoV-2 epidemic wave?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1664-1665.	3.3	3
76	Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature. <i>Clinical Nephrology Case Studies</i> , 2018, 6, 31-35.	0.7	3
77	Role of Raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents. <i>New Microbiologica</i> , 2017, 40, 227-233.	0.1	3
78	Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2014, 9, 41-51.	0.8	2
79	Chemotherapy Mass Campaigns and Migratory Flows: An Unexpected Connection. <i>Clinical Infectious Diseases</i> , 2016, 62, 1323.1-1323.	5.8	2
80	Onychomadesis in a male patient with secondary syphilis. <i>International Journal of STD and AIDS</i> , 2016, 27, 704-705.	1.1	2
81	Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients. <i>Current Hypertension Reviews</i> , 2018, 14, 48-55.	0.9	2
82	Is it time to re-think the use of etravirine in patients with available genotypic resistance test?. <i>Infectious Diseases</i> , 2019, 51, 452-455.	2.8	2
83	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. <i>PLoS ONE</i> , 2020, 15, e0240550.	2.5	2
84	Weight gain and aging in people with HIV. <i>Aids</i> , 2021, 35, 987-989.	2.2	2
85	Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2019, 13, 190-197.	0.8	2
86	Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children. <i>BMC Infectious Diseases</i> , 2022, 22, 55.	2.9	2
87	Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 472-479.	1.1	2
88	Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment. <i>Frontiers in Immunology</i> , 2022, 13, 847816.	4.8	2
89	Pharmacokinetics of Lopinavir Determined with an ELISA Test in Youths with Perinatally Acquired HIV. <i>Indian Journal of Pediatrics</i> , 2014, 81, 856-60.	0.8	1
90	Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 168-170.	1.1	1

#	ARTICLE	IF	CITATIONS
91	Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV. <i>Frontiers in Immunology</i> , 2018, 9, 2447.	4.8	1
92	Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view. <i>Tuberculosis</i> , 2021, 126, 102041.	1.9	1
93	Evaluating fostemsavir as a therapeutic option for patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1539-1545.	1.8	1
94	Migrants and imported disease: Trends of admission in an Italian infectious disease ward during the migration crisis of 2015-2017. <i>BMC Public Health</i> , 2020, 20, 738.	2.9	1
95	Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. <i>Sexually Transmitted Infections</i> , 2022, , sextrans-2021-055289.	1.9	1
96	Role of [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Diagnosis and Treatment of Sarcoidosis in an HIV-2-Infected Patient. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 868-869.	1.1	0
97	Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment. <i>Aids</i> , 2018, 32, 1202-1203.	2.2	0
98	Immunonutrition in Human Immunodeficiency Virus Infection: Which Populations to Target?. <i>Clinical Infectious Diseases</i> , 2019, 69, 2228-2229.	5.8	0
99	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. <i>Journal of Virus Eradication</i> , 2019, 5, 47-49.	0.5	0
100	Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience. <i>Journal of Women and Aging</i> , 2019, 31, 176-188.	1.0	0
101	Starting HIV therapy in patients with mitochondrial disease. <i>Aids</i> , 2021, 35, 2063-2065.	2.2	0
102	Therapeutic Management of Chronic Hepatitis B in Clinical Practice: A Study in 505 Patients. <i>American Journal of Gastroenterology</i> , 2013, 108, S110.	0.4	0
103	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. <i>Journal of Virus Eradication</i> , 2019, 5, 47-49.	0.5	0
104	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. , 2020, 15, e0237831.		0
105	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. , 2020, 15, e0237831.		0